Amsel Medical

Executive Summary

Amsel Medical is a pre-commercialization medical device company developing the SCureClamp™ with Interdigitation Occlusion Technology (iDOT™), a minimally invasive mechanical clamping device for occluding vessels and tubular structures. Founded in 2011 and now based in San Diego, CA, the company holds FDA clearances and a CE Mark for use in general surgery. Amsel is targeting applications in vascular disease, trauma, and various surgical specialties. The company is in Phase 2 stage, indicating ongoing clinical or regulatory development with a focus on expanding indications and securing commercialization partnerships. Given its validated technology and regulatory approvals, Amsel is well-positioned to address unmet needs in surgical occlusion, but its pre-revenue status carries execution risk. Conviction score: 65.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for expanded indications in vascular surgery75% success
• Q1 2027Strategic partnership or distribution agreement for US commercial launch60% success
• Q2 2026Series B or later-stage financing round to support commercialization50% success